SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot

SGLT2i use

SGLT2i have been shown to reduce risk for mortality, progression of chronic kidney disease,
 and cardiovascular outcomes in these populations. Yet, because SGLT2i can have an acute
 hemodynamic effect on kidney function, in clinical practice providers are wary of providing
 these medications to patients who have established indications but recently had acute kidney
 injury (AKI).
 
 This is a pilot interventional study to collect process-data (measures of recruitment and
 measures of adherence) that can be used to establish feasibility for a larger pilot
 randomized trial in the future. The study aims to conduct a small randomized intervention
 trial with two arms, with approximately 10-12 patients in the intervention arm and 5-6 in the
 control arm. The intervention will be providing a prescription for a SGLT2i based on
 established criteria for this FDA-approved class of drugs, and the control will be usual care
 (through which, control arm participants will also have access to this FDA-approved class of
 drugs - expect receipt of a SGLT2i in the control arm to be rare, but a degree of crossover
 will be expected).